Identification
NamePanobinostat
Accession NumberDB06603
TypeSmall Molecule
GroupsApproved, Investigational
Description

Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.

Structure
Thumb
Synonyms
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
panobinostat
External IDs LBH589
Product Ingredients
IngredientUNIICASInChI KeyDetails
Panobinostat hydrateD07V79Q44T Not AvailableYUKVPQZUSANPNW-ASTDGNLGSA-NDetails
Panobinostat lactateHN0T99OO4V 960055-56-5XVDWNSFFSMWXJJ-ASTDGNLGSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FarydakCapsule10 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule20 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule20 mg/1OralNovartis2015-02-23Not applicableUs
FarydakCapsule15 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule20 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule10 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule10 mg/1OralNovartis2015-02-23Not applicableUs
FarydakCapsule15 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule20 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule15 mg/1OralNovartis2015-02-23Not applicableUs
FarydakCapsule10 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
FarydakCapsule15 mgOralNovartis Europharm Limited2015-08-28Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII9647FM7Y3Z
CAS number404950-80-7
WeightAverage: 349.434
Monoisotopic: 349.179026993
Chemical FormulaC21H23N3O2
InChI KeyFPOHNWQLNRZRFC-ZHACJKMWSA-N
InChI
InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
IUPAC Name
N-hydroxy(2E)-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enimidic acid
SMILES
[H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO
Pharmacology
Indication

Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.

Structured Indications
PharmacodynamicsNot Available
Mechanism of action

Panobinostat is a deacetylase (DAC) inhibitor. DACs, also known as histone DACs (HDAC), are responsible for regulating the acetylation of about 1750 proteins in the body; their functions are involved in many biological processes including DNA replication and repair, chromatin remodelling, transcription of genes, progression of the cell-cycle, protein degradation and cytoskeletal reorganization. In multiple myeloma, there is an overexpression of DAC proteins. Panobinostat inhibits class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10) and class IV (HDAC 11) proteins. Panobinostat's antitumor activity is believed to be attributed to epigenetic modulation of gene expression and inhibition of protein metabolism. Panobinostat also exhibits cytotoxic synergy with bortezomib, a proteasome inhibitor concurrently used in treatment of multiple myeloma.

TargetKindPharmacological actionActionsOrganismUniProt ID
Histone deacetylaseProtein groupyes
inhibitor
Humannot applicabledetails
Related Articles
Absorption

After a 20 mg dose, panobinostat was quickly absorbed with a time to maximum absorption of 2 hours.

Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Panobinostat was extensively metabolized to 77 metabolites. Unchanged panobinostat recovered in urine and feces was 2% and 3%, respectively. Primary metabolic pathways of panobinostat are reduction, hydrolysis, oxidation, and glucuronidation processes. CYP and non-CYP enzymes were found to play significant role in metabolism, CYP2D6 and CYP2C19 playing minor roles.

Route of eliminationNot Available
Half life

30 hours

ClearanceNot Available
Toxicity

Farydak carries a Boxed Warning alerting patients and health care professionals that severe diarrhea and severe and fatal cardiac events, arrhythmias and electrocardiogram (ECG) changes have occurred in patients receiving Farydak. Because of these risks, Farydak is being approved with a Risk Evaluation and Mitigation Strategy (REMS) consisting of a communication plan to inform health care professionals of these risks and how to minimize them.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe serum concentration of 4-Methoxyamphetamine can be increased when it is combined with Panobinostat.Experimental, Illicit
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Panobinostat.Approved
AcetylcholineThe serum concentration of Acetylcholine can be increased when it is combined with Panobinostat.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Panobinostat.Approved
AfatinibThe serum concentration of Panobinostat can be increased when it is combined with Afatinib.Approved
AjmalineThe serum concentration of Ajmaline can be increased when it is combined with Panobinostat.Approved
AlbendazoleThe serum concentration of Panobinostat can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Panobinostat can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Panobinostat can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Panobinostat can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Panobinostat.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Panobinostat.Approved
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Panobinostat.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Panobinostat.Approved
Aminohippuric acidThe serum concentration of Panobinostat can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Panobinostat.Approved, Withdrawn
AmiodaroneThe serum concentration of Panobinostat can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Panobinostat.Approved
AmlodipineThe serum concentration of Panobinostat can be increased when it is combined with Amlodipine.Approved
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Panobinostat.Approved
AmphetamineThe serum concentration of Amphetamine can be increased when it is combined with Panobinostat.Approved, Illicit
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Panobinostat.Approved
AmsacrineThe serum concentration of Amsacrine can be increased when it is combined with Panobinostat.Approved
AnagrelidePanobinostat may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Panobinostat.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
AprepitantThe serum concentration of Panobinostat can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe serum concentration of Aprindine can be increased when it is combined with Panobinostat.Approved
ArformoterolThe serum concentration of Arformoterol can be increased when it is combined with Panobinostat.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Panobinostat.Approved, Investigational
Arsenic trioxidePanobinostat may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Panobinostat.Approved
AsenapinePanobinostat may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Panobinostat.Approved, Withdrawn
AtazanavirThe serum concentration of Panobinostat can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Panobinostat can be increased when it is combined with Atenolol.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Panobinostat.Approved
AtorvastatinThe serum concentration of Panobinostat can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Panobinostat.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Panobinostat.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Panobinostat.Investigational
BedaquilinePanobinostat may increase the QTc-prolonging activities of Bedaquiline.Approved
BenzatropineThe serum concentration of Benzatropine can be increased when it is combined with Panobinostat.Approved
BenzocaineThe serum concentration of Panobinostat can be increased when it is combined with Benzocaine.Approved
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Panobinostat.Approved
BepridilThe serum concentration of Bepridil can be increased when it is combined with Panobinostat.Approved, Withdrawn
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Panobinostat.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Panobinostat.Approved, Investigational
BexaroteneThe serum concentration of Panobinostat can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Panobinostat can be increased when it is combined with Biperiden.Approved
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Panobinostat.Approved
BoceprevirThe serum concentration of Panobinostat can be increased when it is combined with Boceprevir.Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Panobinostat.Approved, Investigational
BosentanThe serum concentration of Panobinostat can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Panobinostat can be increased when it is combined with Bosutinib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Panobinostat.Approved
BromocriptineThe serum concentration of Panobinostat can be increased when it is combined with Bromocriptine.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Panobinostat.Approved
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Panobinostat.Experimental, Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Panobinostat.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Panobinostat.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Panobinostat.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Panobinostat.Approved
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Panobinostat.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Panobinostat.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Panobinostat.Approved
CanagliflozinThe serum concentration of Panobinostat can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Panobinostat can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Captopril can be increased when it is combined with Panobinostat.Approved
CarbamazepineThe serum concentration of Panobinostat can be decreased when it is combined with Carbamazepine.Approved, Investigational
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Panobinostat.Approved
CarteololThe serum concentration of Carteolol can be increased when it is combined with Panobinostat.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Panobinostat.Approved, Investigational
CaspofunginThe serum concentration of Panobinostat can be increased when it is combined with Caspofungin.Approved
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Panobinostat.Approved, Vet Approved
CeritinibThe serum concentration of Panobinostat can be increased when it is combined with Ceritinib.Approved
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Panobinostat.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Panobinostat.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Panobinostat.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Panobinostat.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Panobinostat.Approved, Vet Approved
ChlorpropamideThe serum concentration of Panobinostat can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Panobinostat can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Panobinostat.Approved
CholesterolThe serum concentration of Panobinostat can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Panobinostat can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Panobinostat can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Panobinostat.Approved
CimetidineThe serum concentration of Panobinostat can be decreased when it is combined with Cimetidine.Approved
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Panobinostat.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
CisapridePanobinostat may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Panobinostat.Approved
ClarithromycinThe serum concentration of Panobinostat can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Panobinostat can be decreased when combined with Clemastine.Approved
ClevidipineThe serum concentration of Clevidipine can be increased when it is combined with Panobinostat.Approved
ClofazimineThe serum concentration of Panobinostat can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Panobinostat.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Panobinostat.Approved
ClotrimazoleThe metabolism of Panobinostat can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Panobinostat.Approved
CobicistatThe serum concentration of Panobinostat can be increased when it is combined with Cobicistat.Approved
CodeineThe serum concentration of Codeine can be increased when it is combined with Panobinostat.Approved, Illicit
ColchicineThe serum concentration of Panobinostat can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Panobinostat can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Panobinostat can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibPanobinostat may increase the QTc-prolonging activities of Crizotinib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Panobinostat.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Panobinostat.Approved, Investigational
CyclosporineThe metabolism of Panobinostat can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Panobinostat can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Panobinostat can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Panobinostat can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Panobinostat.Approved
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Panobinostat.Approved, Investigational
DarunavirThe serum concentration of Panobinostat can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Panobinostat.Approved
DasatinibThe serum concentration of Panobinostat can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Panobinostat can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Panobinostat.Approved
DeferasiroxThe serum concentration of Panobinostat can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Panobinostat.Approved
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Panobinostat.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Panobinostat.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Panobinostat.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Panobinostat.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Panobinostat.Approved
DesloratadineThe serum concentration of Panobinostat can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Panobinostat can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe serum concentration of Dexfenfluramine can be increased when it is combined with Panobinostat.Approved, Illicit, Withdrawn
DexmethylphenidateThe serum concentration of Dexmethylphenidate can be increased when it is combined with Panobinostat.Approved
DextroamphetamineThe serum concentration of Dextroamphetamine can be increased when it is combined with Panobinostat.Approved, Illicit
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Panobinostat.Approved
DiclofenacThe serum concentration of Panobinostat can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Panobinostat.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Panobinostat.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Panobinostat.Approved, Illicit
DihydroergotamineThe metabolism of Panobinostat can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Panobinostat.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Panobinostat.Approved
DipyridamoleThe serum concentration of Panobinostat can be increased when it is combined with Dipyridamole.Approved
DisopyramidePanobinostat may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panobinostat.Approved, Investigational
DofetilidePanobinostat may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDolasetron may increase the arrhythmogenic activities of Panobinostat.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Panobinostat.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Panobinostat.Approved
DopamineThe serum concentration of Dopamine can be increased when it is combined with Panobinostat.Approved
DoxazosinThe serum concentration of Doxazosin can be increased when it is combined with Panobinostat.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Panobinostat.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Panobinostat.Approved, Investigational
DoxycyclineThe metabolism of Panobinostat can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Panobinostat can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Panobinostat.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Panobinostat.Approved
EfavirenzThe serum concentration of Panobinostat can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Panobinostat can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Panobinostat.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Panobinostat.Approved
EnalaprilThe serum concentration of Panobinostat can be increased when it is combined with Enalapril.Approved, Vet Approved
EncainideThe serum concentration of Encainide can be increased when it is combined with Panobinostat.Approved, Withdrawn
EnclomipheneThe serum concentration of Enclomiphene can be increased when it is combined with Panobinostat.Investigational
EnzalutamideThe serum concentration of Panobinostat can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Panobinostat.Approved, Investigational
ErgonovineThe serum concentration of Panobinostat can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Panobinostat can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Panobinostat.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Panobinostat.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Panobinostat can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Panobinostat.Investigational
EstramustineThe serum concentration of Panobinostat can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Panobinostat can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Panobinostat can be decreased when it is combined with Estrone.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Panobinostat.Approved, Illicit
EtoposideThe serum concentration of Panobinostat can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Panobinostat.Approved, Investigational
EtravirineThe serum concentration of Panobinostat can be decreased when it is combined with Etravirine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Panobinostat.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Panobinostat.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Panobinostat.Approved
FelodipineThe serum concentration of Panobinostat can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Panobinostat can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Panobinostat.Approved
FexofenadineThe serum concentration of Panobinostat can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Panobinostat can be increased when it is combined with Fidaxomicin.Approved
FingolimodPanobinostat may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Panobinostat.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Panobinostat.Approved
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Panobinostat.Approved
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Panobinostat.Approved, Vet Approved
FlupentixolPanobinostat may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Panobinostat.Approved
FlurazepamThe serum concentration of Panobinostat can be increased when it is combined with Flurazepam.Approved, Illicit
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Panobinostat.Approved
FluvoxamineThe serum concentration of Fluvoxamine can be increased when it is combined with Panobinostat.Approved, Investigational
FormoterolThe serum concentration of Formoterol can be increased when it is combined with Panobinostat.Approved, Investigational
FosamprenavirThe metabolism of Panobinostat can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Panobinostat can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Panobinostat.Approved
FosphenytoinThe serum concentration of Panobinostat can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Panobinostat can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Panobinostat is combined with G17DT.Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Panobinostat.Approved
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Panobinostat.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Panobinostat.Approved, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
GenisteinThe serum concentration of Panobinostat can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Panobinostat can be increased when it is combined with Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Panobinostat.Approved
Gramicidin DThe serum concentration of Panobinostat can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the arrhythmogenic activities of Panobinostat.Approved, Investigational
GrepafloxacinThe serum concentration of Panobinostat can be increased when it is combined with Grepafloxacin.Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Panobinostat.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Panobinostat.Approved
HalothaneThe serum concentration of Halothane can be increased when it is combined with Panobinostat.Approved, Vet Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Panobinostat.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Panobinostat.Approved, Illicit
HydrocortisoneThe serum concentration of Panobinostat can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Panobinostat.Approved, Illicit
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Panobinostat.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Panobinostat.Approved
IbutilidePanobinostat may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe serum concentration of Idarubicin can be increased when it is combined with Panobinostat.Approved
IdelalisibThe serum concentration of Panobinostat can be increased when it is combined with Idelalisib.Approved
IloperidoneThe serum concentration of Iloperidone can be increased when it is combined with Panobinostat.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Panobinostat.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Panobinostat.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Panobinostat.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Panobinostat.Approved
IndinavirThe serum concentration of Panobinostat can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Panobinostat can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Panobinostat is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Panobinostat is combined with INGN 225.Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Panobinostat.Approved
IsavuconazoniumThe metabolism of Panobinostat can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Panobinostat.Approved
ItraconazoleThe serum concentration of Panobinostat can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Panobinostat.Approved
IvacaftorThe serum concentration of Panobinostat can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Panobinostat can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Panobinostat.Approved
KetamineThe serum concentration of Panobinostat can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Panobinostat can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Panobinostat.Approved
LansoprazoleThe serum concentration of Panobinostat can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Panobinostat is combined with Leflunomide.Approved, Investigational
LenvatinibPanobinostat may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
LevodopaThe serum concentration of Levodopa can be increased when it is combined with Panobinostat.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Panobinostat.Approved
LevothyroxineThe serum concentration of Panobinostat can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Panobinostat.Approved, Vet Approved
LiothyronineThe serum concentration of Panobinostat can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Panobinostat can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Panobinostat can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe serum concentration of Lisuride can be increased when it is combined with Panobinostat.Approved
LithiumLithium may increase the QTc-prolonging activities of Panobinostat.Approved
LomitapideThe serum concentration of Panobinostat can be increased when it is combined with Lomitapide.Approved
LomustineThe serum concentration of Lomustine can be increased when it is combined with Panobinostat.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Panobinostat.Approved
LopinavirThe serum concentration of Panobinostat can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Panobinostat.Approved
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Panobinostat.Approved
LosartanThe serum concentration of Panobinostat can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Panobinostat can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Panobinostat can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Panobinostat can be decreased when it is combined with Lumacaftor.Approved
LumefantrinePanobinostat may increase the QTc-prolonging activities of Lumefantrine.Approved
MaprotilineThe serum concentration of Maprotiline can be increased when it is combined with Panobinostat.Approved
MebendazoleThe serum concentration of Panobinostat can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Panobinostat.Approved
Megestrol acetateThe serum concentration of Panobinostat can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MephenytoinThe serum concentration of Mephenytoin can be increased when it is combined with Panobinostat.Investigational, Withdrawn
MeprobamateThe serum concentration of Panobinostat can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Panobinostat.Approved
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Panobinostat.Approved
MethadoneThe serum concentration of Methadone can be increased when it is combined with Panobinostat.Approved
MethamphetamineThe serum concentration of Methamphetamine can be increased when it is combined with Panobinostat.Approved, Illicit
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Panobinostat.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Panobinostat.Approved, Vet Approved
MethylphenidateThe serum concentration of Methylphenidate can be increased when it is combined with Panobinostat.Approved, Investigational
MethyprylonThe serum concentration of Methyprylon can be increased when it is combined with Panobinostat.Approved, Illicit, Withdrawn
MetoclopramideThe serum concentration of Metoclopramide can be increased when it is combined with Panobinostat.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Panobinostat.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Panobinostat.Approved
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Panobinostat.Approved
MianserinThe serum concentration of Mianserin can be increased when it is combined with Panobinostat.Approved
MibefradilThe serum concentration of Panobinostat can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Panobinostat can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Panobinostat can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
MinaprineThe serum concentration of Minaprine can be increased when it is combined with Panobinostat.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Panobinostat.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Panobinostat.Approved
MitomycinThe serum concentration of Panobinostat can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Panobinostat can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Panobinostat can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe serum concentration of Moclobemide can be increased when it is combined with Panobinostat.Approved
ModafinilThe serum concentration of Panobinostat can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Panobinostat.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Panobinostat.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
NafcillinThe serum concentration of Panobinostat can be decreased when it is combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Panobinostat can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Panobinostat can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Panobinostat is combined with Natalizumab.Approved, Investigational
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Panobinostat.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Panobinostat.Approved, Investigational
NefazodoneThe serum concentration of Panobinostat can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Panobinostat can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Panobinostat can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Netupitant can be increased when it is combined with Panobinostat.Approved
NevirapineThe serum concentration of Panobinostat can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Panobinostat.Approved
NicergolineThe serum concentration of Nicergoline can be increased when it is combined with Panobinostat.Approved
NicotineThe serum concentration of Nicotine can be increased when it is combined with Panobinostat.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Panobinostat.Approved
NilotinibPanobinostat may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Panobinostat can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Panobinostat can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Panobinostat can be increased when it is combined with Nitrendipine.Approved
NitrofuralThe serum concentration of Nitrofural can be increased when it is combined with Panobinostat.Approved, Vet Approved
NorethisteroneThe serum concentration of Panobinostat can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Panobinostat.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Panobinostat.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Panobinostat.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Panobinostat.Approved, Investigational
OlaparibThe metabolism of Panobinostat can be decreased when combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Panobinostat.Experimental
OlodaterolOlodaterol may increase the QTc-prolonging activities of Panobinostat.Approved
OmeprazoleThe serum concentration of Panobinostat can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the arrhythmogenic activities of Panobinostat.Approved
OsimertinibThe serum concentration of Panobinostat can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Panobinostat.Approved
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Panobinostat.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Panobinostat.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
P-NitrophenolThe serum concentration of Panobinostat can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Panobinostat.Approved, Vet Approved
PalbociclibThe serum concentration of Panobinostat can be increased when it is combined with Palbociclib.Approved
PaliperidonePanobinostat may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Panobinostat can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Panobinostat can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Paroxetine can be increased when it is combined with Panobinostat.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Panobinostat.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Panobinostat.Approved
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Panobinostat.Approved
PentobarbitalThe serum concentration of Panobinostat can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Panobinostat.Approved
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Panobinostat.Approved
PerindoprilThe serum concentration of Panobinostat can be increased when it is combined with Perindopril.Approved
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Panobinostat.Approved
PethidineThe serum concentration of Pethidine can be increased when it is combined with Panobinostat.Approved
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Panobinostat.Withdrawn
PhenforminThe serum concentration of Phenformin can be increased when it is combined with Panobinostat.Approved, Withdrawn
PhenobarbitalThe serum concentration of Panobinostat can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Panobinostat can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Panobinostat.Approved, Investigational
PimozidePanobinostat may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe serum concentration of Pindolol can be increased when it is combined with Panobinostat.Approved
PiperazineThe serum concentration of Piperazine can be increased when it is combined with Panobinostat.Approved, Vet Approved
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Panobinostat.Approved
Platelet Activating FactorThe serum concentration of Panobinostat can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Panobinostat.Approved
PosaconazoleThe serum concentration of Panobinostat can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Panobinostat can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Panobinostat can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Panobinostat can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Panobinostat.Approved
PrimidoneThe serum concentration of Panobinostat can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Panobinostat can be increased when it is combined with Probenecid.Approved
ProcainamideThe serum concentration of Procainamide can be increased when it is combined with Panobinostat.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Panobinostat.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Panobinostat.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Panobinostat.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Panobinostat.Approved
PropofolThe serum concentration of Propofol can be increased when it is combined with Panobinostat.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Panobinostat.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Panobinostat.Approved
PseudoephedrineThe serum concentration of Pseudoephedrine can be increased when it is combined with Panobinostat.Approved
QuercetinThe serum concentration of Panobinostat can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Panobinostat.Approved
QuinacrineThe serum concentration of Panobinostat can be increased when it is combined with Quinacrine.Approved
QuinidinePanobinostat may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Panobinostat.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Panobinostat.Approved
RanolazineThe serum concentration of Panobinostat can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Panobinostat can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Panobinostat can be increased when it is combined with Regorafenib.Approved
RemoxiprideThe serum concentration of Remoxipride can be increased when it is combined with Panobinostat.Approved, Withdrawn
ReserpineThe serum concentration of Panobinostat can be decreased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Panobinostat can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Panobinostat can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Panobinostat can be decreased when it is combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Panobinostat.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Panobinostat is combined with CDX-110.Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Panobinostat.Approved, Investigational
RitonavirThe serum concentration of Panobinostat can be increased when it is combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Panobinostat.Approved
RolapitantThe serum concentration of Panobinostat can be increased when it is combined with Rolapitant.Approved
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Panobinostat.Approved
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Panobinostat.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Panobinostat.Approved
SaquinavirThe serum concentration of Panobinostat can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Panobinostat can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Panobinostat can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Panobinostat.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be increased when it is combined with Panobinostat.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Panobinostat.Approved, Investigational
SiltuximabThe serum concentration of Panobinostat can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Panobinostat can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Panobinostat.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Panobinostat.Approved
SirolimusThe serum concentration of Panobinostat can be decreased when it is combined with Sirolimus.Approved, Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Panobinostat.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
SotalolPanobinostat may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe serum concentration of Sparteine can be increased when it is combined with Panobinostat.Experimental
SpironolactoneThe serum concentration of Panobinostat can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Panobinostat is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Panobinostat can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Panobinostat can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Panobinostat can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Panobinostat can be decreased when it is combined with Streptozocin.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Panobinostat.Approved
SulfinpyrazoneThe serum concentration of Panobinostat can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
SumatriptanThe serum concentration of Panobinostat can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
TacrineThe serum concentration of Panobinostat can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Panobinostat.Approved, Investigational
TacrolimusThe serum concentration of Panobinostat can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Panobinostat resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Panobinostat.Approved, Investigational
TapentadolThe serum concentration of Tapentadol can be increased when it is combined with Panobinostat.Approved
Taurocholic AcidThe serum concentration of Panobinostat can be increased when it is combined with Taurocholic Acid.Experimental
TegaserodThe serum concentration of Tegaserod can be increased when it is combined with Panobinostat.Investigational, Withdrawn
TelaprevirThe serum concentration of Panobinostat can be increased when it is combined with Telaprevir.Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Panobinostat.Approved
TelithromycinThe serum concentration of Panobinostat can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Panobinostat can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Panobinostat can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Panobinostat can be increased when it is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Panobinostat.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Panobinostat.Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be increased when it is combined with Panobinostat.Investigational
TestosteroneThe serum concentration of Panobinostat can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Panobinostat.Approved
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Panobinostat.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Panobinostat.Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Panobinostat.Approved
TicagrelorThe serum concentration of Panobinostat can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Ticlopidine can be increased when it is combined with Panobinostat.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Panobinostat.Approved
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Panobinostat.Approved
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Panobinostat.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Panobinostat.Approved
TocilizumabThe serum concentration of Panobinostat can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPanobinostat may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Panobinostat.Approved, Investigational
TolvaptanThe serum concentration of Panobinostat can be increased when it is combined with Tolvaptan.Approved
ToremifenePanobinostat may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Panobinostat.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Panobinostat.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Panobinostat.Approved, Investigational
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Panobinostat.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
TrifluoperazineThe serum concentration of Panobinostat can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Panobinostat can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Panobinostat.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Panobinostat.Approved, Vet Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Panobinostat.Approved
VandetanibPanobinostat may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Panobinostat.Approved
VemurafenibPanobinostat may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Panobinostat.Approved
VerapamilThe metabolism of Panobinostat can be decreased when combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Panobinostat.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Panobinostat.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Panobinostat.Approved
VincristineThe serum concentration of Panobinostat can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Panobinostat.Approved, Investigational
VoriconazoleThe serum concentration of Panobinostat can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Panobinostat.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Panobinostat.Approved, Vet Approved
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Panobinostat.Approved
ZimelidineThe serum concentration of Panobinostat can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidonePanobinostat may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Panobinostat.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Panobinostat.Approved, Investigational
Food InteractionsNo interactions found.
References
Synthesis ReferenceNot Available
General References
  1. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006 Jan 15;12(2):634-42. [PubMed:16428510 ]
  2. Laubach JP, Moreau P, San-Miguel JF, Richardson PG: Panobinostat for the Treatment of Multiple Myeloma. Clin Cancer Res. 2015 Nov 1;21(21):4767-73. doi: 10.1158/1078-0432.CCR-15-0530. Epub 2015 Sep 11. [PubMed:26362997 ]
  3. Link [Link]
  4. Drugs of the Future - Panobinostat [Link]
External Links
ATC CodesL01XX42 — Panobinostat
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (772 KB)
MSDSDownload (227 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnBasic ScienceCancer, Breast1
1Active Not RecruitingOtherNasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour1
1Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Advanced Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndromes1
1Active Not RecruitingTreatmentIdiopathic Myelofibrosis / Post Essential Thrombocythemia Myelofibrosis / Post Polycythemia-Vera Myelofibrosis1
1Active Not RecruitingTreatmentMelanoma / Skin Cancers1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)2
1Active Not RecruitingTreatmentMultiple Myeloma in Relapse1
1Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Tumors, Solid1
1Active Not RecruitingTreatmentPlasma Cell Myeloma2
1CompletedNot AvailableAdvanced Solid Tumors2
1CompletedTreatmentAcute Myeloid Leukaemias (AML)2
1CompletedTreatmentAcute Myeloid Leukaemias (AML) / Chronic Myelomonocytic Leukemia (CMML) / Myelodysplastic Syndromes (MDS)1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumors / Cancers1
1CompletedTreatmentCancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCancers1
1CompletedTreatmentCutaneous T-Cell Lymphoma (CTCL) / Tumors1
1CompletedTreatmentEsophageal Cancers / HEAD & NECK Cancer / Prostate Cancer1
1CompletedTreatmentHER-2 Positive Breast Cancer / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentHead and Neck Carcinoma / Lung Cancers1
1CompletedTreatmentHodgkins Disease (HD) / Lymphoblastic Leukemia, Acute, Childhood / Myelogenous Leukemia, Acute, Childhood / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemias1
1CompletedTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentMalignant Melanoma / Melanoma1
1CompletedTreatmentMantle Cell Lymphoma (MCL)1
1CompletedTreatmentMesothelioma / Non-Small-Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentNeoplasms / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
1RecruitingTreatmentColorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer / Colorectal Cancers / Non-small Cell Lung Carcinoma (Adenocarcinoma) / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
1RecruitingTreatmentGliomas1
1RecruitingTreatmentSickle Cell Disorders1
1TerminatedTreatmentBrain Metastasis / High-grade Meningioma / Recurrent Gliomas1
1TerminatedTreatmentHormone Refractory Prostate Cancer1
1TerminatedTreatmentHormone Refractory Prostate Cancer Disease1
1TerminatedTreatmentLiver Cancer1
1TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1TerminatedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
1TerminatedTreatmentMultiple Myeloma (MM)1
1TerminatedTreatmentRecurrent Colon Cancer / Recurrent Rectal Cancer / Stage IV Colon Cancer / Stage IV Rectal Cancer1
1TerminatedTreatmentTumors, Solid1
1Unknown StatusTreatmentChordomas1
1Unknown StatusTreatmentHepatocellular,Carcinoma1
1Unknown StatusTreatmentLymphoma, Hodgkins1
1WithdrawnTreatmentLung Cancers1
1, 2Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
1, 2Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / B-cell Adult Acute Lymphoblastic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Splenic Marginal Zone Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAgnogenic Myeloid Metaplasia1
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentKahler Disease / Multiple Myeloma (MM) / Myeloma, Plasma-Cell / Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)2
1, 2Active Not RecruitingTreatmentPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase / Post-Essential Thrombocythemia Related Myelofibrosis / Primary Myelofibrosis1
1, 2CompletedTreatmentAcute Myeloblastic Leukemia1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD)1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2CompletedTreatmentLeukemia, Myeloid, Acute / Myelodysplastic Syndromes1
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM)1
1, 2CompletedTreatmentLymphoma, Hodgkins1
1, 2CompletedTreatmentMalignant Gliomas1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMetastatic Melanoma1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentProstate Cancer / Prostatic Neoplasms1
1, 2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2TerminatedTreatmentCancer, Breast1
1, 2TerminatedTreatmentCancer, Breast / Neoplasms, Breast / Tumors, Breast1
1, 2TerminatedTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2WithdrawnTreatmentMultiple Myeloma (MM)1
2Active Not RecruitingBasic ScienceLymphoma in Leukemic Phase / Lymphoma With Cutaneous Involvement / Marrow Involvement With Lymphoma / Multiple Myeloma (MM) / Nodal Lymphoma1
2Active Not RecruitingTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2Active Not RecruitingTreatmentNeoplasms, Hematologic1
2Active Not RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
2CompletedPreventionProstate Cancer1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Refractory Leukemia1
2CompletedTreatmentAnaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) / Angioimmunoblastic T-Cell Lymphoma / Enteropathy- Type T-cell Lymphoma / Extranodal NK/T-cell Lymphoma Nasal Type / Hepatosplenic T-Cell Lymphoma / Peripheral T-cell Lymphoma (Not Otherwise Specified) / Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentClassical Hodgkin's Lymphoma (i.e. Nodular Sclerosing, Mixed-cellularity, Lymphocyte-rich, Lymphocyte-depleted)1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentNeuroendocrine Tumors1
2CompletedTreatmentPost-Essential Thrombocytopenia / Post-Polycythaemia Vera / Primary Myelofibrosis1
2CompletedTreatmentRenal Cell Adenocarcinoma1
2CompletedTreatmentSmall Cell Lung Carcinoma1
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2CompletedTreatmentThyroid Carcinoma1
2RecruitingPreventionGraft Versus Host Disease (GVHD)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentMultiple Myeloma (MM)4
2RecruitingTreatmentRelapse/Refractory Multiple Myeloma1
2TerminatedNot AvailableRecurrent Malignant Gliomas1
2TerminatedTreatmentAdult T-cell lymphomas/leukaemias / Cutaneous T-Cell Lymphoma (CTCL)1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMetastatic Gastric Cancers1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentMyelodysplastic Syndrome1
2TerminatedTreatmentMyelodysplastic Syndromes (MDS)2
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2WithdrawnTreatmentChronic Graft Versus Host Disease1
2WithdrawnTreatmentMalignant Lymphomas1
2WithdrawnTreatmentMultiple Myeloma (MM)1
2WithdrawnTreatmentRecurrent Glioblastoma1
2, 3CompletedTreatmentChronic Myeloid Leukemia in Chronic Phase1
2, 3CompletedTreatmentCutaneous T-Cell Lymphoma (CTCL)2
2, 3CompletedTreatmentLeukemia,Myeloid, Chronic1
3CompletedTreatmentLymphoma, Hodgkins1
3CompletedTreatmentMultiple Myeloma (MM)1
4CompletedTreatmentMultiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed and Bortezomib Refractory Multiple Myeloma1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM)1
Not AvailableNo Longer AvailableNot AvailableMultiple Myeloma (MM)1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral10 mg
CapsuleOral10 mg/1
CapsuleOral15 mg
CapsuleOral15 mg/1
CapsuleOral20 mg/1
CapsuleOral20 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7067551 No2001-08-312021-08-31Us
US6833384 No2001-09-302021-09-30Us
US8883842 No2008-06-132028-06-13Us
US6552065 No2001-08-312021-08-31Us
US7989494 No2008-01-172028-01-17Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000834 mg/mLALOGPS
logP3.28ALOGPS
logP1.54ChemAxon
logS-5.6ALOGPS
pKa (Strongest Acidic)5.45ChemAxon
pKa (Strongest Basic)10.01ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area80.64 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity106.02 m3·mol-1ChemAxon
Polarizability40.54 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassIndoles and derivatives
Direct ParentTryptamines and derivatives
Alternative ParentsCinnamic acids and derivatives / 3-alkylindoles / Styrenes / Phenylmethylamines / Benzylamines / Aralkylamines / Substituted pyrroles / Heteroaromatic compounds / Hydroxamic acids / Amino acids and derivatives
SubstituentsCinnamic acid or derivatives / Tryptamine / 3-alkylindole / Indole / Benzylamine / Phenylmethylamine / Styrene / Aralkylamine / Benzenoid / Substituted pyrrole
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorssecondary amino compound, hydroxamic acid, cinnamamides, methylindole (CHEBI:85990 )

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transcription regulatory region sequence-specific dna binding
Specific Function:
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Deacetylates SP proteins, SP1 and SP3, and regulates their function. Component of the BRG1-RB1-HDAC1 complex, which negatively regulates the CREST-mediated transcription in resting neurons. Upon calcium stimulation, HDAC1 is released from the complex and CREBBP is recruited, which facilitates transcriptional activation. Deacetylates TSHZ3 and regulates its transcriptional repressor activity. Deacetylates 'Lys-310' in RELA and thereby inhibits the transcriptional activity of NF-kappa-B. Deacetylates NR1D2 and abrogates the effect of KAT5-mediated relieving of NR1D2 transcription repression activity. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. Involved in CIART-mediated transcriptional repression of the circadian transcriptional activator: CLOCK-ARNTL/BMAL1 heterodimer. Required for the transcriptional repression of circadian target genes, such as PER1, mediated by the large PER complex or CRY1 through histone deacetylation.
Components:
NameUniProt IDDetails
Histone deacetylase 1Q13547 Details
Histone deacetylase 10Q969S8 Details
Histone deacetylase 11Q96DB2 Details
Histone deacetylase 2Q92769 Details
Histone deacetylase 3O15379 Details
Histone deacetylase 4P56524 Details
Histone deacetylase 5Q9UQL6 Details
Histone deacetylase 6Q9UBN7 Details
Histone deacetylase 7Q8WUI4 Details
Histone deacetylase 8Q9BY41 Details
Histone deacetylase 9Q9UKV0 Details
References
  1. Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, Sanders K: Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer. 2007 Sep 1;121(5):1138-48. [PubMed:17455259 ]
  2. Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE: Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 2006 Dec 1;66(23):11298-304. [PubMed:17145876 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Richardson PG, Harvey RD, Laubach JP, Moreau P, Lonial S, San-Miguel JF: Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016;9(1):35-48. doi: 10.1586/17512433.2016.1096773. Epub 2015 Oct 26. [PubMed:26503877 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
References
  1. Richardson PG, Harvey RD, Laubach JP, Moreau P, Lonial S, San-Miguel JF: Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016;9(1):35-48. doi: 10.1586/17512433.2016.1096773. Epub 2015 Oct 26. [PubMed:26503877 ]
  2. Bailey H, Stenehjem DD, Sharma S: Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med. 2015 Oct 8;6:269-76. doi: 10.2147/JBM.S69140. eCollection 2015. [PubMed:26504410 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
References
  1. Bailey H, Stenehjem DD, Sharma S: Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med. 2015 Oct 8;6:269-76. doi: 10.2147/JBM.S69140. eCollection 2015. [PubMed:26504410 ]
Drug created on March 19, 2008 10:40 / Updated on August 08, 2017 11:09